|
| 36691849 | Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants. | Antivir Ther | 2023 |
| 37199270 | A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults. | Antivir Ther | 2023 |
| 35485332 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults. | Antivir Ther | 2021 |
| 30899086 | Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. | Br J Cancer | 2019 |
| 28929359 | Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial. | Breast Cancer Res Treat | 2018 |
| 28425345 | Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques. | Stat Methods Med Res | 2018 |
| 29656866 | Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)" [Eur J Cancer 75 (April 2017) 5-13]. | Eur J Cancer | 2018 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 28027521 | Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. | Eur J Cancer | 2017 |
| 28084333 | Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Mod Pathol | 2017 |
| 28477490 | Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial. | Eur J Cancer | 2017 |
| 28214658 | An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>). | Eur J Cancer | 2017 |
| 28292559 | Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Eur J Cancer | 2017 |
| 28527420 | Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. | Eur J Cancer | 2017 |
| 26820652 | Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. | Breast Cancer Res Treat | 2016 |
| 27557300 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. | N Engl J Med | 2016 |
| 25578377 | Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. | Eur J Cancer | 2015 |
| 26488192 | [Axillary lymph node dissection versus axillary radiotherapy in patients with a positive sentinel node: the AMAROS trial]. | Ned Tijdschr Geneeskd | 2015 |
| 26025767 | Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. | Eur J Cancer | 2015 |
| 25638681 | Radiotherapy or surgery for the axilla in node-positive breast cancer?--authors' reply. | Lancet Oncol | 2015 |
| 25467016 | Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. | Ann Oncol | 2015 |
| 24469641 | Mammographic screening detects low-risk tumor biology breast cancers. | Breast Cancer Res Treat | 2014 |
| 24667714 | High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. | Ann Oncol | 2014 |
| 24529560 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. | Lancet | 2014 |
| 25439688 | Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. | Lancet Oncol | 2014 |